Overall market sentiment has been high on Leap Therapeutics Inc (LPTX) stock lately. LPTX receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
Leap Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on LPTX!
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With LPTX Stock Today?
Leap Therapeutics Inc (LPTX) stock is lower by -5.51% while the S&P 500 has gained 0.17% as of 10:00 AM on Wednesday, Aug 16. LPTX is lower by -$0.14 from the previous closing price of $2.54 on volume of 34,800 shares. Over the past year the S&P 500 has risen 3.45% while LPTX is lower by -83.22%. LPTX lost -$7.57 per share in the over the last 12 months.
To screen for more stocks like Leap Therapeutics Inc click here.
More About Leap Therapeutics Inc
Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P100, P102, P204,and P205.
Click Here to get the full Stock Report for Leap Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
